Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 18/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 18/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.61 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 10/20 | 0.58 |
| ▸ | BCR | P11274 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22065199 | 0.90 | DDR1 (0.63) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL29864626 | 0.86 | DDR2 (0.71) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL22065200 | 0.85 | DDR2 (0.60) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL22772380 | 0.83 | DDR1 (0.67) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL21974820 | 0.80 | DDR2 (0.56) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL13219735 | 0.79 | DDR2 (0.68) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL25339278 | 0.79 | DDR2 (0.60) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL30211944 | 0.79 | DDR2 (0.60) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL22025455 | 0.79 | DDR2 (0.65) | DDR1DDR2NTRK1NTRK3NTRK2 | |
| SCHEMBL2976022 | 0.79 | KIT (0.68) | DDR1DDR2NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | DDR1 1422/4885DDR2 2054/4885NTRK1 425/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | DDR1 1422/4885DDR2 2054/4885NTRK1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.